Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

DNA Damage can Stall the Cell Cycle

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...

DNA Damage Can Stall the Cell Cycle

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...

Restarting Stalled Replication Forks

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Overview of DNA Repair

Overview of DNA Repair

In order to be passed through generations, genomic DNA must be undamaged and error-free. However, every day, DNA in a cell undergoes several thousand to a million damaging events by natural causes and external factors. Ionizing radiation such as UV rays, free radicals produced during cellular respiration, and hydrolytic damage from metabolic reactions can alter the structure of DNA. Damages caused include single-base alteration, base dimerization, chain breaks, and cross-linkage.
Chemically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Computational design, synthesis, and in vitro evaluation of thiadiazole-derived PARP-1 inhibitors.

Journal of receptor and signal transduction research·2026

Same author

Medicinal Chemistry Perspectives on Molecular Targets and Targeted Therapeutic Strategies in Breast Cancer.

Mini reviews in medicinal chemistry·2026

Same author

PROTAC-Mediated Targeting of PARP via CRBN: Mechanistic Insights, Resistance Challenges, and Therapeutic Advancements.

Mini reviews in medicinal chemistry·2026

Same author

Integrated computational-based design of putative dual TrkA/TrkB agonists for Alzheimer's disease: pharmacophore modelling, docking, MM/GBSA, DFT and dynamics studies.

Frontiers in bioinformatics·2026

Same author

Correction: Tallapaneni et al. Growth Factor Loaded Thermo-Responsive Injectable Hydrogel for Enhancing Diabetic Wound Healing. <i>Gels</i> 2023, <i>9</i>, 27.

Gels (Basel, Switzerland)·2026

Same author

Sublingual Drug Delivery Systems: Quality by Design Principles, Applications, Market Landscape, and Innovative Technologies.

Current drug delivery·2026

Search research articles

Related Experiment Video

Updated: Jan 14, 2026

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Understanding DNA and PARP in Cancer: Tackling Inhibitor Resistance.

Hardha Balachandran¹, Gowramma Byran¹, Veera Venkata Satyanarayana Reddy Karri²

¹Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

Drug Metabolism and Bioanalysis Letters

|October 20, 2025

Summary

This summary is machine-generated.

Poly (ADP-ribose) polymerases (PARPs) are key in DNA repair. PARP inhibitors (PARPi) show cancer treatment promise, but resistance is a challenge, driving research into new strategies.

Keywords:

DNA DNA repair PARP PARP inhibitors cancer combination therapy.drug efflux homologous recombination repair predictive biomarkers resistance

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Experiment Videos

Last Updated: Jan 14, 2026

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Area of Science:

Molecular Biology
Genetics
Cancer Therapeutics

Background:

Deoxyribonucleic acid (DNA) damage necessitates repair pathways for genomic stability.
Poly (ADP-ribose) polymerases (PARPs) are crucial enzymes in DNA damage detection and repair.
PARP inhibitors (PARPi) target cancer cells with DNA repair deficiencies, like those with BRCA1/2 mutations.

Purpose of the Study:

To review the evolution of PARP inhibitors (PARPi).
To elucidate mechanisms of PARPi resistance.
To explore novel strategies for overcoming PARPi resistance in cancer therapy.

Main Methods:

Literature review on PARP inhibitors and DNA repair.
Analysis of mechanisms contributing to PARPi resistance.
Exploration of emerging therapeutic strategies and combination therapies.

Main Results:

PARPi are effective against certain cancers but face significant resistance.
Resistance mechanisms include restoration of homologous recombination repair and PARP1 mutations.
Combination therapies and novel agents are being investigated to overcome resistance.

Conclusions:

Understanding PARPi resistance mechanisms is vital for improving cancer treatment.
Developing more effective PARPi and predictive biomarkers will enhance therapeutic outcomes.
Future research focuses on durable and targeted PARPi-based cancer therapies.